Suppr超能文献

识别滥用药物患者的抗凝风险。

Identifying the risks of anticoagulation in patients with substance abuse.

机构信息

Department of Medicine, Section of General Internal Medicine, Boston University School of Medicine, 72 East Concord Street, Evans 124, Boston, MA, 02118, USA,

出版信息

J Gen Intern Med. 2013 Oct;28(10):1333-9. doi: 10.1007/s11606-013-2453-x. Epub 2013 Apr 26.

Abstract

BACKGROUND

Warfarin is effective in preventing thromboembolic events, but concerns exist regarding its use in patients with substance abuse.

OBJECTIVE

Identify which patients with substance abuse who receive warfarin are at risk for poor outcomes.

DESIGN

Retrospective cohort study. Diagnostic codes, lab values, and other factors were examined to identify risk of adverse outcomes.

PATIENTS

Veterans AffaiRs Study to Improve Anticoagulation (VARIA) database of 103,897 patients receiving warfarin across 100 sites.

MAIN MEASURES

Outcomes included percent time in therapeutic range (TTR), a measure of anticoagulation control, and major hemorrhagic events by ICD-9 codes.

RESULTS

Nonusers had a higher mean TTR (62 %) than those abusing alcohol (53 %), drugs (50 %), or both (44 %, p < 0.001). Among alcohol abusers, an increasing ratio of the serum hepatic transaminases aspartate aminotransferase/alanine aminotransferase (AST:ALT) correlated with inferior anticoagulation control; normal AST:ALT ≤ 1.5 predicted relatively modest decline in TTR (54 %, p < 0.001), while elevated ratios (AST:ALT 1.50-2.0 and > 2.0) predicted progressively poorer anticoagulation control (49 % and 44 %, p < 0.001 compared to nonusers). Age-adjusted hazard ratio for major hemorrhage was 1.93 in drug and 1.37 in alcohol abuse (p < 0.001 compared to nonusers), and remained significant after also controlling for anticoagulation control and other bleeding risk factors (1.69 p < 0.001 and 1.22 p = 0.003). Among alcohol abusers, elevated AST:ALT >2.0 corresponded to more than three times the hemorrhages (HR 3.02, p < 0.001 compared to nonusers), while a normal ratio AST:ALT ≤ 1.5 predicted a rate similar to nonusers (HR 1.19, p < 0.05).

CONCLUSIONS

Anticoagulation control is particularly poor in patients with substance abuse. Major hemorrhages are more common in both alcohol and drug users. Among alcohol abusers, the ratio of AST/ALT holds promise for identifying those at highest risk for adverse events.

摘要

背景

华法林在预防血栓栓塞事件方面有效,但人们对其在滥用物质的患者中的应用存在担忧。

目的

确定接受华法林治疗的滥用物质患者中哪些患者有发生不良结局的风险。

设计

回顾性队列研究。通过诊断代码、实验室值和其他因素来确定不良结局的风险。

患者

退伍军人事务部改善抗凝治疗研究(VARIA)数据库中的 103897 名在 100 个地点接受华法林治疗的患者。

主要观察指标

结果包括治疗范围内时间百分比(TTR),这是衡量抗凝控制的一个指标,以及 ICD-9 编码的大出血事件。

结果

非使用者的平均 TTR(62%)高于酗酒者(53%)、药物滥用者(50%)或两者兼有者(44%,p<0.001)。在酗酒者中,血清肝转氨酶天冬氨酸氨基转移酶/丙氨酸氨基转移酶(AST:ALT)比值的增加与抗凝控制不良相关;正常 AST:ALT≤1.5 预测 TTR 相对适度下降(54%,p<0.001),而比值升高(AST:ALT 1.50-2.0 和>2.0)则预示着抗凝控制越来越差(49%和 44%,p<0.001 与非使用者相比)。药物滥用和酒精滥用的主要出血风险的年龄调整后的危险比分别为 1.93 和 1.37(与非使用者相比,p<0.001),并且在控制抗凝控制和其他出血风险因素后仍然具有统计学意义(1.69,p<0.001 和 1.22,p=0.003)。在酗酒者中,AST:ALT 升高>2.0 对应于出血增加三倍以上(HR 3.02,p<0.001 与非使用者相比),而正常比值 AST:ALT≤1.5 预测出血率与非使用者相似(HR 1.19,p<0.05)。

结论

在滥用物质的患者中,抗凝控制尤其差。酒精和药物使用者的大出血更为常见。在酗酒者中,AST/ALT 比值有望确定发生不良事件的风险最高的人群。

相似文献

1
Identifying the risks of anticoagulation in patients with substance abuse.识别滥用药物患者的抗凝风险。
J Gen Intern Med. 2013 Oct;28(10):1333-9. doi: 10.1007/s11606-013-2453-x. Epub 2013 Apr 26.
2
Stratifying the risks of oral anticoagulation in patients with liver disease.对肝病患者口服抗凝治疗的风险进行分层。
Circ Cardiovasc Qual Outcomes. 2014 May;7(3):461-7. doi: 10.1161/CIRCOUTCOMES.113.000817. Epub 2014 May 13.
3
Outcomes of anticoagulation therapy in patients with mental health conditions.患有精神健康疾病患者的抗凝治疗结果。
J Gen Intern Med. 2014 Jun;29(6):855-61. doi: 10.1007/s11606-014-2784-2. Epub 2014 Feb 19.
9
Pathways to poor anticoagulation control.导致抗凝控制不佳的因素。
J Thromb Haemost. 2014 May;12(5):628-34. doi: 10.1111/jth.12530.

引用本文的文献

本文引用的文献

4
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
5
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验